Corporate Philosophy


Our Mission is to strive towards Better Health and a Brighter Future for people worldwide through leading innovation in medicine

Vision 2025

We serve the needs of our patients, wherever they are.We earn the trust of society and customers through Takeda-ism. We are recognized as best in class because of agility and innovation, qualities that help us build a steady pipeline and deliver growth, year on year.



Strategic Roadmap

The steps to achieving our Vision are set out in our strategy:
will focus on Values, People, R&D, and Business Performance, as they will help us to progress toward Vision 2025. They need to be reviewed regularly to make sure we stay on track. 



Takeda-ism (Integrity, Fairness, Honesty, Perseverance) and the four priorities (Patient, Trust, Reputation, Business) are deeply ingrained in our ways of working to ensure our commitment to quality and that we do the right thing - at all times.

Takeda is building a patient-centric and customer-centric organization. Our local organizations are empowered to respond in the best way to customer needs.
Our employees have the possibility to develop and thrive in a diverse and agile organization.

Takeda leaders demonstrate strategic thinking, find innovative ways to serve patients, build trust with society, reinforce our reputation, and grow the business. They create an environment that inspires and enables people to collaborate and move the organization forward. They focus on our few designated priorities and deliver superior results. And they elevate the capabilities of our organization now and for the future


Takeda has a focused, world-class R&D innovation engine, making an impact on patients' lives by translating science into life-changing medicines. We focus our research efforts on oncology, gastroenterology (GI), and central nervous system (CNS) therapeutic areas where we want to be at the cutting edge of innovation.

We also have exciting late-stage vaccine candidates for dengue and norovirus, and early research programs in specialty cardiovascular diseases. We conduct research both internally and externally, with the ambition to be considered among the best partners in the industry


Date of Preparation : December 2017